Circulating Tumor DNA in Peripheral T-cell Lymphomas
Next-Generation Sequencing-based, Tumor- and Plasma-informed Droplet Digital PCR Assay for Detection of Circulating Tumor DNA in Peripheral T-cell Lymphomas
University of Aarhus
50 participants
Mar 1, 2024
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance in a cohort of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphomas (PTCL).
Eligibility
Inclusion Criteria7
- Patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma.
- All primary systemic PTCL entities from the International Consensus Classification 2022.
- ≥18 years of age.
- Life expectancy of 3 months or longer.
- ECOG performance status 0-4 at study entry (PS4 only if lymphoma-induced).
- Measurable disease.
- Written informed consent.
Exclusion Criteria15
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Adult T-cell leukemia / lymphoma
- Aggressive NK-cell leukemia
- Primary cutaneous T-cell lymphoma such as Sézary syndrome and Mycosis fungoides.
- Primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
- Lymphomatoid papulosis.
- Primary cutaneous anaplastic large cell lymphoma.
- Primary cutaneous small/medium CD4-positive T-cell lymphoproliferative disorder.
- Primary cutaneous gamma-delta T-cell lymphoma.
- Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder.
- Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.
- History of active cancer during the past year, except basal cell carcinoma of the skin or stage 0 cervical carcinoma (in situ).
- Unwillingness or inability to comply with the study protocol.
Interventions
Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.
FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06362148